PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects
Stock Information for PhaseBio Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.